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In an effort to improve the efficiency of the TSQ 7000 LC-MS/MS system for identification of
drug metabolites in biological matrices in support of drug discovery programs, a combination
of instrument control language procedures for the Finnigan MAT TSQ 7000 mass spectrom-
eter, referred to as INTAMS, were composed. INTAMS was designed to conduct unattended,
automatic liquid chromatography/mass spectrometry (LC-MS) and LC-MS/MS analyses of
drugs and metabolites in commonly encountered in vitro biological matrices. A novel peak
detection algorithm was developed to automatically detect and record the pseudomolecular
ions and retention times of chromatographic components, even if not fully resolved. This
algorithm was used in combination with an automated technique for predicting the molecular
weights of metabolites based on incremental changes of the molecular weight of the parent
drug resulting from well-known biotransformation processes. When applied to a sample of an
incubation mixture of the HIV protease inhibitor Indinavir with a rat liver S9 preparation, the
results obtained by the automatic metabolite detection procedures for LC-MS and LC-MS/MS
analyses in real time were the same as those which were determined manually, by a
knowledgeable operator. (J Am Soc Mass Spectrom 1999, 10, 175–183) © 1999 American
Society for Mass Spectrometry
In response to the increasing demands within thepharmaceutical industry to develop therapeuticagents more rapidly, a significant change has taken
place in the process by which novel lead drug candi-
dates are synthesized. The development of automated
synthetic methods has resulted in a large increase in the
number of drug candidates being evaluated in the
discovery phase [1, 2]. It follows that the accelerated
synthesis of new drug candidates has led to increased
demands upon analytical methodologies used in the
evaluation of those drugs. To keep pace with these
demands, analytical productivity also must increase,
whether it be via the acquisition of additional instru-
mentation and operator personnel and/or increased
efficiency of the use of existing equipment and man-
power.
In the quest to design drugs of high potency, selec-
tivity, safety, and appropriate duration of action, the
chemist must take into consideration drug disposition
characteristics, given that these properties will deter-
mine how much of a drug reaches its site of action and
how long it will remain there. Thus pharmacokinetic
studies in the early stages of drug discovery make a key
contribution to the process of identifying new lead
compounds by providing information on oral bioavail-
ability and drug disposition [3]. To keep pace with the
increasing number of new compounds requiring phar-
macokinetic evaluation, technologies for automated
high throughput bioanalyses are being developed ag-
gressively [4–7].
When the pharmacokinetic properties of a drug are
found to be unsuitable, the cause often is an underlying
metabolic instability. Providing biotransformation data
early in the drug discovery process can assist the
chemist in designing new compounds with maximal
metabolic stability and also minimal toxicity. Our lab-
oratory is involved in studies of the biotransformation
of drug candidates, utilizing liquid chromatography in
conjunction with tandem mass spectrometry [liquid
chromatography-mass spectrometry/mass spectrome-
try (LC-MS/MS)] as the primary analytical tool for the
identification of drug metabolites in biological matrices.
In the realm of drug discovery, our efforts are dedicated
to metabolite identification for the fulfillment of three
objectives: (1) to characterize metabolic “soft spots” in
order to provide the chemist with information that will
be useful in the design of more metabolically stable
compounds, (2) to identify drug metabolites in order
that they may be synthesized and then tested for
pharmacological activity, and (3) to detect products of
metabolic activation, through which reactive, poten-
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tially toxic metabolites are generated, and whose for-
mation can be suppressed or eliminated by appropriate
structural modification.
It was first demonstrated over a decade ago that
LC-MS/MS could be utilized for the structural charac-
terization of metabolites in biological matrices [8]. Since
that time, the process of introducing samples directly
into the mass spectrometer via on-line high-perfor-
mance liquid chromotography (HPLC) separation (LC-
MS) has proven to be considerably less time consuming
and less labor intensive than off-line chromatographic
isolation of metabolites prior to mass spectral analysis.
In conjunction with on-line sample introduction,
MS/MS capabilities have made possible the acquisition
of structurally informative data from pseudomolecular
ions of analytes of interest, even when they are not
chromatographically resolved.
The latest generation of Finnigan MATs (San Jose,
CA) triple quadrupole instruments, the TSQ 7000, fea-
tures a powerful data system (icis) which provides a
text editing utility through which operators can con-
struct instrument control language (ICL) procedures of
their own design. This utility makes accessible to the
instrument operator, the software used in the control of
data acquisition. This accessibility provides users with a
broad variety of options for developing and customiz-
ing instrument control procedures for their own specific
needs.
In 1995, Finnigan MAT reported advances made in
the automation of acquisition of LC-MS/MS data by
using the TSQ 7000. Three commercial ICL procedures,
namely “retention time dependent,” “data dependent,”
and “signal dependent” automated LC-MS/MS were
described and made available for use (and potential
modification) by the customer base [9]. Retention time
dependent automated LC-MS/MS is a very useful tech-
nique for the acquisition of product ion spectra if the
molecular masses and chromatographic retention char-
acteristics of the analytes of interest are known. Obvi-
ously, a prior analysis of the sample by full scan LC-MS
is required before retention time dependent LC-MS/MS
can be put to good use.
Data dependent automated LC-MS/MS is a power-
ful technique which makes possible the acquisition of
product ion spectra of analytes of known molecular
weight, even if there is no available retention behavior
information. Unfortunately, without prior analysis of
the sample by LC-MS to determine the molecular
masses of the analytes of interest, the pseudomolecular
ions which the automatic LC-MS/MS procedure will
“see” are limited to those which the analyst can predict.
Data dependent LC-MS/MS requires full scan LC-MS
analysis to be carried out during a chromatographic
analysis until a predetermined ion of interest elutes, at
which time the procedure switches the TSQ 7000 into
product ion scanning MS/MS mode. After a predeter-
mined number of MS/MS scans are performed, the
instrument switches back to full scan MS mode, until
another, or the same analyte of interest is detected.
Signal dependent automatic LC-MS/MS calls for the
switching from full scan LC-MS analysis to product ion
scanning MS/MS mode each time the ion current signal
from any chromatographic component exceeds a preset
threshold value. Theoretically, this type of procedure
can allow for the complete MS/MS analysis of any
predictable or non-predictable metabolites in a sample
in a single chromatographic run. Unfortunately, be-
cause of the large difference in ion currents generated
by full scan and product ion scanning analyses, chro-
matograms generated by data and signal dependent
automatic LC-MS/MS procedures appear disjointed
and do not actually reveal discrete peaks. We have
determined that, for our purposes, both a full scan
LC-MS chromatographic analysis and at least one prod-
uct ion scanning LC-MS/MS analysis are required for
the characterization of any one sample. A full scan
LC-MS analysis of each sample for metabolite identifi-
cation is desirable in that such analyses generate chro-
matograms which are valuable visual aids for imagin-
ing a compound of interest’s metabolic profile. Because
of the differing ionization potentials between analytes,
such ion current chromatograms do not give a reliable
quantitative description of the metabolites as would a
HPLC radiochromatogram. However, they can give the
viewer information regarding the number of metabo-
lites present in the matrix analyzed and whether a
metabolite of interest might be present as a major or
minor component, based very roughly on peak area.
In 1995, Cole et al. [10] developed an automated
LC-MS/MS procedure for metabolite identification
with the TSQ 7000, known as rapid automated biotrans-
formation identification (RABID). RABID represented a
breakthrough in the development of automated LC-
MS/MS methodology for the rapid identification of
drug metabolites. In this procedure, samples of drug
metabolites generated in vivo or in vitro are subjected
initially to full scan LC-MS analysis. During that anal-
ysis, RABID detects any component whose pseudomo-
lecular ion’s mass-to-charge ratio differs from that of
the parent drug by a mass increment which might arise
from a common biotransformation process, e.g. the
addition of 16 mass units resulting from oxidation of
the parent drug. RABID records the pseudomolecular
ions of these predictable metabolites and their retention
times from the initial full scan LC-MS analysis and
utilizes that information in a second analysis which
constitutes a retention time dependent automated LC-
MS/MS procedure. RABID can obtain LC-MS and LC-
MS/MS data on many metabolites of a drug in a
complex mixture in two chromatographic analyses,
with nothing known in advance about the parent drug
other than its molecular weight. Automated procedures
modeled after RABID have been used successfully in
our laboratory but have been found lacking in their
ability to detect and obtain data from metabolites such
as products of O- and N-dealkylation (often major
routes of biotransformation) if the structure of the
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parent compound has not been studied in advance of
the analyses.
Contained herein is a description of the first step we
have taken to accelerate and automate metabolite iden-
tification by LC-MS/MS in our laboratory while main-
taining the highest standards of quality and complete-
ness. By building on the advances made in automated
LC-MS/MS technology by Finnigan MAT and Cole et
al. and by developing a novel, real-time peak detection
algorithm, we have sought to increase the efficiency of
operation of our existing TSQ 7000 LC-MS/MS systems
and minimize the involvement of operators. Although
increased efficiency is desirable for all aspects of our
work, the procedures described here are ideally suited
for the analysis of samples generated from in vitro
systems and thus are readily applicable to the support
of drug discovery.
Traditionally, discovery support analyses in our lab-
oratory were carried out using the sequence of proce-
dures listed in the following scheme, applied to samples
generated by the incubation of drug candidates in
appropriate in vitro systems, such as liver microsomal
or S9 preparations.
1. Perform full-scan LC-MS analyses of incubation
samples.
*2. Manually process chromatographic data generated
from full-scan analyses. Record the retention times
of chromatographic peaks observed in recon-
structed total ion current chromatograms and the
corresponding mass-to-charge ratios of precursor
ions which give rise to those peaks.
*3. Construct an ICL procedure to generate product ion
spectra of the pseudomolecular ions of the drug and
its metabolites.
4. Perform the required product ion scanning LC-
MS/MS analysis or analyses. (In many cases, prod-
uct ion spectra can be obtained for all metabolites in
a single analysis.)
*5. Manually process product ion spectral data.
6. Interpret product ion spectra to characterize the
structures of metabolites.
A generic ICL procedure is used for the performance of
all full scan analyses, so the initiation of Step 1 requires
only the click of a mouse button. The analyses, obvi-
ously, can be carried out unattended. Once the full scan
analyses are complete, however, the chromatographic
data must be processed and the operator must deter-
mine which precursor ions correspond to chromato-
graphic peaks observed in reconstructed total ion cur-
rent chromatograms (Step 2). Once drug metabolite
peaks are identified, the mass-to-charge ratios of their
pseudomolecular ions and retention times are recorded
manually. The operator then composes a retention-time
dependent product ion scanning ICL procedure to
obtain product ion spectra for as many metabolites as
possible in one analysis (Step 3). Once product ion
scanning ICL procedures have been generated, the
analyses can be carried out unattended (Step 4). After
the data have been collected, they are processed man-
ually (Step 5). Step 6 involves the interpretation of
product ion spectra for the characterization of metabo-
lites and, at present, must be done manually by an
analyst with significant expertise in spectral interpreta-
tion and a sound knowledge of biotransformation pro-
cesses.
Steps 2, 3, 5, and 6 (marked with an asterisk) tradi-
tionally require operator involvement and can be labor
intensive and time consuming. Obviously, if there is no
operator present, as there tends not to be during the
overnight hours, the analysis sequence cannot proceed
from Step 2 to Step 3 and beyond. It was the goal of the
work described here to automate Steps 2 and 3 to
reduce the amount of labor involved in their execution
and to permit the analysis sequence to proceed, unat-
tended, from Step 1 through Step 4. Achievement of the
goal will result in reduction of the manpower require-
ment and the extent of overnight delays involved in
metabolite identification.
To demonstrate the capabilities of the automated pro-
cedures described here, the Merck HIV protease inhibitor,
Indinavir. (N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-tertiary-
butyl-aminocarbonyl-4-(3-pyridylmethyl)piperazino]4(S)-
hydroxy-2(R)-phenylmethylpentanamide, Crixivan, Fig-
ure 1) was chosen as a model compound to generate
metabolites for detection. The metabolism of Indinavir in
several species has been reported [11, 12].
Experimental
Biological Methods
Indinavir was incubated with rat liver S9 fractions at a
substrate concentration or 20 mM and a protein concen-
tration of 5 mg mL21 in 100 mM potassium phosphate
buffer at pH 7.4. Reactions were initiated by the addi-
tion of nicotinamide adenine dinucleotide phosphate
reduced form (NADPH) to give a final cofactor concen-
tration of 1 mM. Each incubation mixture (1 mL total
volume) was shaken in a water bath kept at 37°C for 1 h.
Reactions were terminated by the addition of two
volumes of ice-cold acetonitrile. The samples were then
vortex mixed and centrifuged. The supernatants were
dried and the residues reconstituted in a 1 mL volume
of 0.1% formic acid in water and acetonitrile (95:5, v/v).
Aliquots (15 mL) then were injected onto HPLC.
HPLC
HPLC was carried out on a Hewlett-Packard HP1050
gradient HPLC system consisting of a solvent delivery
system and an autosampler. Separation was carried out
on an Ultrasphere (Beckman, Fullerton, CA) C18 column
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(2 mm 3 15 cm, 5 m) using a mobile phase consisting of
0.1% formic acid in water (solvent “A”) and 0.1% formic
acid in acetonitrile (solvent “B”) and a constant flow
rate of 0.2 mL min21. The gradient used was as follows:
Isocratic conditions of 5% B were maintained for 2 min
followed by a linear increase to 20% B in 3 min. This
was followed by a second linear increase to 50% B in 35
min. The column then was washed with 80% B for 3 min
and equilibrated at 5% B for 15 min prior to each
injection.
Mass Spectrometry
The HPLC system described was interfaced to a Finni-
gan TSQ 7000 tandem mass spectrometer. Both the
mass spectrometer and the HPLC were controlled from
a DEC 3000 Alpha station operating with icis Version
8.2. Mass spectral analyses were carried out using
electrospray ionization (ESI) in the positive ion mode,
with the ESI ionizing voltage maintained at 5.0 kV for
all analyses. The temperature of the heated capillary
inlet was maintained at 230 °C and the multiplier volt-
age was 1700 V. For full scan analyses, the first quad-
rupole was scanned from m/z 180 to m/z 850 in 0.7 s.
A scan range lower limit of m/z 180 was selected to
preclude the observation of solvent cluster ions which
might otherwise appear as base peak ions in the full
scan mass spectra. Tandem mass spectrometry (MS/
MS) was based on collision-induced dissociation (CID)
of ions entering the rf-only octapole region where argon
was used as the collision gas at a pressure of 1.7 mtorr.
All product ion scans were carried out over the mass
range of m/z 50 to a value 10 Da greater than the mass
of the precursor ion, with a scan time of 0.5 s. The
optimal collision offset (ECID) for Indinavir, defined as
the collision energy required to reduce the intensity of
the precursor ion ([M 1 H]1 5 m/z 614) to ;30% of
that of the base peak in the product ion spectrum (m/z
421, Figure 1), was determined to be 230 eV.
Results and Discussion
As stated previously, one of the advantages that the
Finnigan TSQ 7000 offers over other commercially
available MS/MS systems is the capability of writing
ICL procedures that can control the mass spectrometer
in the performance of user-customized tasks. The elec-
tronics of the TSQ 7000 system allow for rapid param-
eter switching on time scales which are compatible with
those used typically in routine HPLC separations. Ta-
bles, referred to as “user lists,” are available to the
instrument’s operator and serve as interactive data
bases in which data can be stored temporarily, analyzed
mathematically and subsequently used for control of
the instrument’s acquisition parameters. The INTAMS
(“Intelligent Automated LC-MS/MS”) procedure de-
scribed here is composed of two programs (packages of
ICL procedures written in our laboratory) and requires
Figure 1. Product ion spectrum generated upon CID of the (M 1 H)1 ion (m/z 614) of Indinavir
(Crixivan). Proposed origins of product ions are also shown.
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two separate chromatographic analyses for each sam-
ple. The first program is executed during the full scan
analysis of the first chromatographic run of a particular
sample and is actually a decision-making program. A
logic diagram of this procedure is shown in Figure 2.
While the mass spectrometer is conducting a full scan
analysis during the first chromatographic run, the pro-
gram records the mass-to-charge ratio and the intensity
associated with the base peak ion from each scan in a
continuously updated data base. After performing an
arithmetic data smoothing procedure over overlapping
series of scans in real time, the program performs a
peak detection task in order to determine if the ion
current from the base peak of a series of scans actually
constitutes a “chromatographic peak.” This peak detec-
tion task involves performing an arithmetic manipula-
tion on the smoothed ion current signals and making
corrections for noise on these signals at each point in
time. Intensities of individual smoothed data points are
denoted Ii, which in any single case is the average
intensity of the signal of the base peak ion in scan
numbers i-4, i-3, i-2, i-1 and i, provided the mass-to-
charge ratio of the base peak ion in each of these scans
is constant. Noise is determined arithmetically at each
scan number i (Ni) by averaging the intensity of the
tenth most abundant peak in each full scan spectrum
over the preceding 20 scans. Peak detection criteria are
fulfilled if the ratio of a smoothed, noise-corrected base
peak ion intensity at any scan number (i 1 5), and the
same value determined for the corresponding scan
number i, referred to as S(i15), equals or exceeds a
minimum value of 1.4, i.e.
S~i15! 5
~I~i15! 2 N~i15!!
~Ii 2 Ni!
If S(i15) is determined at any point in a LC-MS analysis
to equal or exceed a value of 1.4, INTAMS records the
mass-to-charge ratio of the recurring base peak ion and
the retention time corresponding to scan (i 1 5) in a
data base. That data base is accessed during a second
chromatographic analysis of the same sample. The
process, used for the detection of base peak metabolite
precursor ions has been given the abbreviation BID
(“base peak ion detection”). BID is also capable of
detecting components of mixtures which are not well-
resolved chromatographically. If the intensity of the
second most intense ion in any particular scan reaches
25% of that of the base peak, BID will record that ion’s
mass-to-charge ratio in the data base and perform the
same smoothing and peak detection tasks as were
carried out on the base peak ion. If the chromatographic
peak criteria are met by the second most intense ion,
BID records the mass-to-charge ratio of the ion and its
associated elution-start time in the data base as well.
While BID is being executed, an additional process,
referred to as DED (predetermined precursor ion detec-
tion), searches for any predictable metabolite precursor
ions that might not appear as base peak ions. Predeter-
mined metabolite precursor ion mass-to-charge ratio
values are chosen to reflect common pathways of xeno-
biotic metabolism. Table 1 shows a list of formulae for
the determination of mass-to-charge ratios of such
pseudomolecular ions as a function of the molecular
weight of the parent drug. Also shown are the meta-
bolic processes from which such metabolites might be
Figure 2. Logic diagram of a package of instrument control
language procedures used for the automatic acquisition and
real-time analysis of LC-MS data. The program performs a peak
detection task which also records pseudomolecular ions and
elution start times of drugs and metabolites in vitro.
Table 1. Mass-to-charge ratios of predetermined metabolites
(expressed as functions of the molecular weight of the parent
drug) and the common biotransformation process(es) from
which they might be derived
Metabolite precursor ion m/z
(addition to [M 1 H]1)
Type of biotransformation
(Phase I)
116 Addition of oxygen
114 Addition of oxygen &
two-electron oxidation
130 Addition of oxygen (2) &
two-electron oxidation
132 Addition of oxygen (2)
118 Hydration
136 Hydration (2)
22 Two-electron oxidation
12 Two-electron reduction
214 Demethylation
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derived. During the initial LC-MS analysis, signals
produced from any such ions are subjected to the same
peak detection analysis by DED as were base peak ions
by BID. If any predetermined metabolite precursor ions
are found to constitute actual chromatographic peaks,
their mass-to-charge ratios and elution-start times are
recorded in the same data base as were the peaks
detected by BID.
In total, BID and DED produce a data base which
lists the mass-to-charge ratios of the base peak ions of
all components, second most intense peaks which are at
least 25% as abundant as the base peak and also any
predetermined metabolite precursor ions which corre-
spond to actual chromatographic peaks, whether or not
they are fully resolved chromatographically. Recorded
along with these values is the run time at which each
legitimate chromatographic entity began to elute. If
there are any results duplicated by the two peak detec-
tion functions, the second entry is automatically ig-
nored by the retention-time dependent product ion
scanning algorithm which is carried out during the
second chromatographic analysis of the sample. This is
made possible by a postacquisition “clean-up” ICL
procedure composed in our laboratory which simplifies
the data base generated during the INTAMS full scan
LC-MS analysis. This procedure converts table entries
which have closely similar retention times and precur-
sor ions of identical nominal mass to a single table
entry. This procedure has proven to be key to the
successful application to INTAMS.
Because there are two different precursor metabolite
detection sensors functioning simultaneously during
the first chromatographic analysis, the program is able
to detect chromatographic peaks which are only par-
tially separable by chromatography and many compo-
nents which actually co-elute. The bottom trace in
Figure 3 depicts a reconstructed total ion current chro-
matogram which was generated manually following
the completion of a full-scan LC-MS analysis of an
extract from a rat liver S9 incubation with Indinavir.
The ion current traces above it were extracted manually
by an operator who was searching for chromatographic
peaks generated from base peak ions and from pseudo-
molecular ions of predicted metabolites. Chromato-
graphic peaks which were determined by the operator
to be unrelated to the parent drug, by visual compari-
son with the ion current trace generated from analysis
of a control sample (an incubation mixture containing
all cofactors but no drug), were not extracted for
display. All of the peaks from the full scan LC-MS
analysis which were determined by the operator to be
pertinent also were detected by either BID or DED and
are shown (in addition to those from some non-drug-
related components) in a data base in Table 2. It is
apparent that BID and DED did not “miss” any metab-
olites which were detectable by the operator.
A second package of ICL procedures was written to
conduct automatic LC-MS/MS analysis of an incuba-
tion extract during a second chromatographic run. This
second program automatically accesses the data base
which was generated by BID and DED during the
previous full-scan LC-MS analysis and performs prod-
uct ion scanning of pseudomolecular ions of the parent
drug and its metabolites. From the data base, the second
program selects the pseudomolecular ions from which
product ion spectra are to be generated during the
run-time interval in which each component is expected
to elute. A logic diagram of this automated LC-MS/MS
procedure is shown in Figure 4.
INTAMS allows for the mass range scanned by the
third quadrupole to be automatically adjusted for each
individual precursor ion. In order to accommodate the
possible shifts in retention times between runs, an
adequate acquisition window width is automatically set
for each ion. If a reference value is provided before the
analysis for the optimal collision energy (Ecid) for the
parent drug, rotating collision offset values of Ecid 2 15
V, Ecid and Ecid 1 15 V are used to provide the maxi-
mum number of interpretable product ions from each
eluting component. Product ion scans of overlapping
series of metabolite precursor ions in the data base are
carried out until the retention time is within 0.3 min of
Figure 3. Reconstructed ion current chromatograms generated
from full scan LC-MS analysis of an incubation of Indinavir with
rat liver S9. The bottom trace represents the total ion current. The
other single-ion current traces were manually extracted by an
operator who selected mass-to-charge ratios corresponding to
base peak ions and pseudomolecular ions of predicted metabo-
lites.
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the elution start time of the next metabolite precursor
ion in the data base (Figure 4). In this manner, possible
shifts in retention time between runs are taken into
consideration.
Figure 5 shows proposed structures, product ion
spectral data and spectral interpretations correspond-
ing to rat liver S9 metabolites of Indinavir, M1–M6,
respectively. In addition to three products of monohy-
droxylation of the parent drug, two N-dealkylation
products and a product of both N-dealkylation and
mono-hydroxylation were observed. A seventh metab-
olite (dihydroxylated product, M7) was detected but the
information derived from the corresponding product
ion spectrum was insufficient for structural character-
ization. Product ion spectra of other components were
generated by INTAMS, but interpretation of the spectra
led to the conclusion that these components were not
drug related. The findings of the metabolite identifica-
tion exercise described here correlate well with the
findings from other laboratories [11, 12].
INTAMS has been demonstrated to eliminate the
requirement for operator involvement during the pro-
cess of collecting LC-MS and LC-MS/MS data in mix-
tures generated from in vitro incubations of drugs,
without compromising the quality of the results. If a
time of 45 min is assumed for each chromatographic
analysis, without the use of INTAMS, an operator can
extract metabolite precursor ions from LC-MS data and
write retention time dependent ICL procedures for
approximately ten samples per work day. The LC-
MS/MS analyses of those same samples can be carried
out overnight to complete the full analyses of 10 sam-
ples in about 8 additional hours. This amounts to the
full analysis of 10 samples in a 24 hour period. With the
availability of INTAMS and an assumed run time of 45
min, at least 15 samples can be fully analyzed in a 24
hour period. In addition, no operator involvement is
required in the process after initiating the batch of
analyses. This gives the operator the freedom to per-
form other tasks while the analyses are being carried
out, such as interpretation of data acquired the pre-
vious day. The use of INTAMS for sample analysis
allows the operator to spend a much larger fraction of
working hours devoted to spectral interpretation,
which currently is the rate-limiting process in metab-
olite identification. Devoting a larger fraction of the
available manpower to “the bottleneck” has had a
profound impact on the overall productivity of our
laboratory.
INTAMS, as it has been described here, has been
used in our laboratory since March 1997, and has
doubled our laboratory’s production of data with re-
spect to the support of drug discovery programs. The
preliminary version of INTAMS described here, which
involves full scan LC-MS analysis as the first step, is
likely to be applicable only to samples where few
endogenous substances are found to co-elute with
Table 2. A data base generated by the intelligent peak
detection sensors, BID and DED, during a full scan LC-MS
analysis of an incubation of Indinavir with rat liver S9; the data
were accessed automatically by a product ion scanning program
in a second chromatographic analysis of the same sample
Precursor ion (m/z)
Elution start time
(min)
377.098a 12.441
475.913a 12.720
319.043a 12.866
469.395a 13.107
564.475a 13.493
483.332a 14.689
630.200a,b 15.952
391.257a 16.352
630.200a,b 16.552
646.200b 17.807
539.372a 18.099
614.472a 19.255
630.200b 21.587
523.343a 21.681
505.368a 24.142
aDetected by BID.
bDetected by DED.
Figure 4. Logic diagram of a program used for automated
product ion scanning of pseudomolecular ions of drugs and
metabolites in biological media. From a data base generated
during a previous full scan LC-MS analysis of the same sample,
this program selects precursor ions for MS/MS analysis during
the run-time interval in which each peak is expected to elute.
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drug-related materials and the drug-related compo-
nents are present in concentrations which are high in
comparison to the concentration of endogenous sub-
stances. To be useful in the identification of drug
metabolites in samples generated from studies carried
out in vivo, such as urine or bile, scan modes more
specific than full scan analysis may need to be used for
the initial, metabolite detection phase of INTAMS.
INTAMS is currently under further development in our
laboratory for potential use in the identification of in
vivo drug metabolites. Promising results have been
obtained, thus far, using methods of scanning for
precursor ions and and/or neutral losses characteris-
tic of the MS/MS behavior of the parent drug (and
some predictable metabolites) as means of detecting
drug-related materials in samples from in vivo stud-
ies.
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